The PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity, while PIM-1 and PIM-3 are positive regulators, report Medical University of South Carolina investigators in The Journal of Clinical Investigation. Blocking PIM-2 in allogeneic bone marrow transplant dramatically accelerated graft-versus-host disease. In adoptive immunotherapy with autologous T cells, silencing PIM-2 on T cells produced robust tumor immunity, highlighting the importance of PIM-specific inhibition.
- Journal of Clinical Investigation
- Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina; National Institutes of Health; Department of Defense, SmartState Endowment in Cancer Stem Cell Biology & Therapy Program